

Clinical trials of disopyramide

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
disopyramide vs placebo			
Karlson , 1998 n=46/46 follow-up: 12 months	Disopyramide 500 mg/d versus placebo	Persistent AF between 6 weeks and 1 year	Parallel groups open
Lloyd (Disopyramide vs placebo) , 1984 n=29/25 follow-up: 6 months	Disopyramide 450 mg/d , versus placebo	Persistent AF lasting 1 month to 3 years	Parallel groups double blind
disopyramide vs propafenone			
PRODIS , 1996 n=31/25 follow-up: 6 months	Disopyramide 750 mg/d versus propafenone 900 mg/d	Persistent AF	Parallel groups double blind
disopyramide vs quinidine			
Lloyd (Disopyramide vs quinidine) , 1984 n=29/28 follow-up: 6 months	Disopyramide 450 mg/d , , versus placebo	Persistent AF lasting 1 month to 3 years	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

Karlson, 1998:

Karlson BW, Torstensson I, Abjrn C, Jansson SO, Peterson LE Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284-90 [[3289932](#)]

Karlson BW, Torstensson I, Abjrn C, Kallryd A, Jonsson J, Jansson SO, Peterson LE [Preventive disopyramide after electroconversion of atrial fibrillation—a good alternative] Lakartidningen 1991;88:2242-5 [[2056838](#)]

Lloyd (Disopyramide vs placebo), 1984:

PRODIS, 1996:

Crijns HJ, Gosselink AT, Lie KI Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. *Cardiovasc Drugs Ther* 1996;10:145-52 [[8842506](#)]

Lloyd (Disopyramide vs quinidine), 1984: